Recently, some studies have verified that PD-L1 overexpression indicates poor prognosis in various cancers [15, 43–46], and several anti-PD-L1 monoclonal antibodies, including avelumab, durvalumab and atezolizumab have been approved by the FDA [47–49]. This evidence concerns the gene CD274 and cancer.